On October 27, 2026, Jonathan Dickinson, CEO of Ambio Life Sciences, met with Guy Bertrand Mapangou, president of Gabon's Economic, Social, Environmental and Cultural Council (CESEC), in Libreville. According to GabonReview, Dickinson said he was open to signing a memorandum of understanding with Gabonese authorities to regulate iboga cultivation and help the country retain sovereignty over the resource. No agreement has been signed yet, and GabonReview's report describes exploratory talks, not a finalized deal.
Ambio currently operates ibogaine treatment programs in Mexico and Malta, per the same report. A formal arrangement with Gabon would be the company's first move into the plant's country of origin.
We've been tracking Gabon's push to control its iboga resources more directly. Earlier this month we covered a May 2026 decree regulating iboga use and traditional knowledge, followed by a September 2026 draft decree proposing a full export ban on the plant and its derivatives. Mapangou has been one of the most vocal officials pushing this agenda. GabonReview quotes him arguing that "Le Gabon doit devenir un acteur économique majeur de l'iboga" ("Gabon must become a major economic player in iboga"), and he has repeatedly warned about biopiracy risk, the appropriation of traditional knowledge, and foreign actors capturing the economic upside while Gabon supplies the raw material.
That framing matters for reading this meeting correctly. Mapangou isn't simply welcoming foreign investment. He's negotiating from a position that explicitly names the risk of value extraction, and he's doing it as the head of a constitutional advisory body, not a trade ministry looking to attract capital at any cost.
What's Actually on the Table
GabonReview's report frames the talks around three goals: regulating iboga exploitation, preserving national sovereignty over the resource, and building out a domestic industry rather than remaining a raw-material exporter. Dickinson, for his part, is described as willing to support Gabon in setting up a cooperation framework with the state, and to contribute his clinical experience with ibogaine toward research conducted under Gabonese regulation.
What we don't know yet: whether Gabonese institutions like the Centre International de Recherches Médicales de Franceville (CIRMF) would have a formal research role, whether the arrangement would create training or employment pathways for Gabonese scientists and technicians, and how traditional Bwiti communities, who have cultivated and protected iboga for generations, would be positioned in any resulting framework. GabonReview's article doesn't address these questions directly, and neither Ambio nor the Gabonese government has published further detail since the October 27 meeting.
Why the History Here Isn't Incidental
Iboga's relationship with Gabon carries weight that goes beyond trade policy. In our earlier reporting on the persecution of Bwiti, we documented two decades of raids, torture, and executions carried out by missionaries and colonial administrators in Gabon and Spanish Guinea, justified by a cannibalism myth that was never substantiated. That history is part of why Mapangou's sovereignty language isn't rhetorical flourish. A plant whose practitioners were once criminalized by colonial authorities is now the subject of international commercial interest, and the terms of that interest will determine whether the pattern repeats in a new form or breaks from it.
We're not opposed to international investment in iboga research. Clinical partnerships can fund studies that wouldn't otherwise happen and bring resources to a country that has had little say in how its most culturally significant plant gets commercialized abroad. But investment framed only around supply contracts, with research, intellectual property, and profit concentrated outside Gabon, would reproduce the extraction dynamic Mapangou is explicitly trying to avoid.
What We're Watching
The open questions we'll be tracking as this develops: whether a signed memorandum of understanding follows this meeting, whether it includes specific commitments on local research capacity or revenue sharing, and whether Bwiti communities get a defined role rather than a passing mention. We'll also be watching whether Gabon's September 2026 draft export ban moves forward in parallel, since a domestic processing requirement would materially change what a foreign partnership like this one could look like in practice.
For now, what's confirmed is limited: one meeting, one stated openness to a future agreement, and a framework still being negotiated in principle rather than on paper.